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2016 AGA Institute Council
Section Research Mentor
Awardeesach year, Digestive Disease Week (DDW) bringsEtogether the best clinical, translational, and basic sci-
ence in theﬁeld. It is also anopportunity formany trainees and
young investigators to present their work, receive advice from
senior investigators, and build their professional networks. At
DDW 2016, the American Gastroenterological Association
(AGA) recognized 1 member each from 10 Council sections
who have committed themselves to training these young in-
vestigators and have shown a track record of outstanding
research mentorship. Cellular and Molecular Gastroenterology
and Hepatology extends our appreciation to the awardees in
each section for providing guidance and mentorship to the
next generation of researchers.Cellular and Molecular
Gastroenterology
(CMG) Section: James
R. Goldenring, MD,
PhD, AGAF
James Goldenring received his
AB degree from Harvard College
and his MD and PhD degrees from
Yale University. After residency
training in general surgery from
1986 to 1988 at Yale New Haven
Hospital, he completed a post-
doctoral fellowship in surgical research as an American
College of Surgeons Research Fellow. Dr Goldenring was one
of the founding members of the Institute of Molecular
Medicine at the Medical College of Georgia. Dr Goldenring is
presently the Paul Sanger Professor of Surgery and Profes-
sor of Cell and Developmental Biology and Co-Director of
the Epithelial Biology Center at Vanderbilt University Med-
ical Center. Dr Goldenring’s research spans multiple topics
across the broad area of epithelial biology. He has been a
leader in the investigation of the speciﬁc roles of Rab small
guanosine triphosphatases in regulating vesicle trafﬁcking
and membrane recycling in polarized cells. Most recently, Dr
Goldenring has studied aberrant membrane trafﬁcking in
the context of neonatal congenital diarrhea diseases, espe-
cially in microvillus inclusion disease and MYO5B knockout
mice. Finally, Dr Goldenring has been a leader in the ﬁeld of
gastric cancer research, studying the mechanisms respon-
sible for the induction of metaplasia. His ﬁndings have
shown that preneoplastic metaplasia (spasmolytic
polypeptide-expressing metaplasia) does not arise from
professional mucosal stem cells, but rather from trans-
differentiation of mature chief cells into a proliferativeCellumetaplasia. His recent studies have suggested that targeting
Ras activation may be an effective approach for reversing
metaplasia in the stomach. Dr Goldenring is currently the
Associate Editor of Cellular and Molecular Gastroenterology
and Hepatology and previously was the Associate Editor of
the American Journal of Physiology—Gastrointestinal & Liver
Physiology.Esophageal, Gastric
and Duodenal
Disorders (EGD)
Section: John E.
Pandolﬁno, MD, MSCI,
AGAF
John Pandolﬁno is a Professor
of Medicine and Chief of Gastro-
enterology and Hepatology at the
Feinberg School of Medicine at
Northwestern University. His
career has focused primarily on
studying the biomechanics of bolus transport and gastro-
intestinal motility as it pertains to gastroesophageal reﬂux
and swallowing disorders. He currently is funded by the
National Institutes of Health (NIH) to study gastroesopha-
geal reﬂux disease and dysphagia pathogenesis and also
receives funding from industry focused on the development
of new technologies to investigate and treat gastrointestinal
disorders. He also maintains a strong clinical practice in the
Esophageal Center at Northwestern, which serves as the
nation’s top referral center for complicated esophageal
diseases. He is active in multiple professional organizations
and has a strong commitment to the editorial process,
serving as the Editor-in-Chief of Diseases of the Esophagus,
Associate Editor of the American Journal of Gastroenterology,
and as a member of the editorial board of multiple high-
level gastroenterology and hepatology journals.Gastrointestinal
Oncology (GIONC)
Section: John M.
Carethers, MD, AGAF
John Carethers received his
MD from Wayne State University,
ﬁnished his internal medicine
residency at Massachusetts Gen-
eral Hospital, and completed his
gastroenterology fellowship at the
University of Michigan. Dr Care-
thers joined the faculty at the
University of California (UC) San Diego where he becamelar and Molecular Gastroenterology and Hepatology 2016;2:387–390
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T32 Gastroenterology Training Grant, and Founding Direc-
tor of the UC San Diego Digestive Disease Research Devel-
opment Center. In 2009, Dr Carethers moved to the
University of Michigan, where he is the John G. Searle Pro-
fessor and Chair of the Department of Internal Medicine.
His previous editorial experience includes serving on
several editorial boards, including the American Journal of
Physiology—Gastrointestinal & Liver Physiology, as well
serving as section editor of “This Month in Gastroenter-
ology” for Gastroenterology (2006–2011) and as Senior
Associate Editor for Gastroenterology (2011–2016). His
research interests are in gastroenterology oncology, partic-
ularly the genetics and pathogenesis of colorectal cancer;
familial colorectal cancer; and cancer disparities related to
colorectal cancer. He was elected to the National Academy of
Medicine in 2012 and the American Association of Arts and
Sciences in 2016.Growth, Development
and Child Health
(GDCH) Section:
Samuel Nurko, MD,
MPH
Samuel Nurko is Chief of the
Center for Motility and Functional
Gastrointestinal Disorders at Bos-
ton Children’s Hospital and Profes-
sor of Pediatrics atHarvardMedical
School. Dr Nurko was born and
raised in Mexico City, where he
completed his medical education at the Universidad Nacional
Autonoma de Mexico. He completed his pediatric residency at
Boston City Hospital and Massachusetts General Hospital, and
completed his fellowship in pediatric gastroenterology at
Boston Children’s Hospital, where he created the Center for
Motility and Functional Bowel Disorders. The Center not only
provides state-of-the-art care and evaluation for children with
motility and functional bowel disorders, but has a well-funded
research base, as well as a well-deﬁned educational compo-
nent that allows the training of the next generation of pediatric
gastrointestinal (GI) motility specialists. Dr Nurko has distin-
guished himself during his long tenure as an academic, NIH-
funded clinical researcher, teacher, mentor, and expert in
motility and functional disorders of the gastrointestinal tract in
children. He is a recognized leader in the ﬁeld and has
participated in many national and international committees
and task forces, including being the Chair of the Neonatal/
Toddler Rome IV Committee. Dr Nurko has made major con-
tributions to the understanding of motility and functional GI
disorders in children. His clinical and research interests have
focused on understanding the pathophysiology and estab-
lishing the best approach and treatments for these disorders,
and hehas beena pioneer in the development and validation of
new techniques to study these disorders in the pediatric
population.Imaging and Advanced
Technology (IAT)
Section: William R.
Brugge, MD, AGAF,
FASGE
William Brugge is a teacher-
clinician in the GI Unit at Massa-
chusetts General Hospital. Dr
Brugge’s academic and research
focus involves the ﬁeld of advanced
endoscopy and he was one of the
pioneers in the development of
endoscopic ultrasound (EUS). Although EUS originally was
designed to simply stage gastrointestinal malignancies, it has
evolved into an important diagnostic and therapeutic tech-
nique for endoscopists. The application of EUS in the diag-
nosis, staging, and biopsy of pancreatic malignancies has
been a particularly important focus for Dr Brugge, and he has
concentrated on the diagnosis andmanagement of pancreatic
cystic neoplasms. Dr Brugge led a large multicenter trial,
ﬁnding that EUS imaging morphology and cyst cytology were
relatively nondiagnostic for differentiating between
mucinous and serous cystadenomas. The trial showed that
cyst ﬂuid tumor markers were the most diagnostic tool and
carcinoembryonic antigen was the most accurate marker. Dr
Brugge also has examined the possibility that EUS could be
used as a treatment of cystic neoplasms. EUS-guided ethanol
ablation of cystic neoplasmswas developed at Massachusetts
General Hospital under his direction. In addition to per-
forming endoscopic research in patients, Dr Brugge evaluates
new ablative technologies in an animal laboratory, using
endoscopic ultrasound to guide various ablative catheters
and agents into the pancreas. Dr Brugge’s group has evalu-
ated radiofrequency ablation, photodynamic therapy,
ethanol, and chemotherapeutic agents. Lately, they have
evaluated confocal endomicroscopy for differentiating be-
tween mucinous and nonmucinous cysts.Immunology,
Microbiology and
Inﬂammatory Bowel
Diseases (IMIBD)
Section: William J.
Sandborn, MD, AGAF
William Sandborn completed
medical school and an internal
medicine residency at Loma
Linda University in Loma Linda,
California. He completed a gastro-
enterology fellowship at the Mayo Clinic in Rochester, Min-
nesota in 1993. From 1993 to 2010, he was on the faculty of
the Mayo Clinic, rising to Professor of Medicine, Vice
Chairman of the Division of Gastroenterology and
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Property and Industry Relations. In 2011, he became a Pro-
fessor of Medicine and Adjunct Professor of Surgery at the
University of California San Diego and Director of the IBD
Center and Chief of the Division of Gastroenterology for the
UC San Diego Health System. He is a member of the UC San
Diego Health System Board of Governors and the Clinical
Practice Operations Board (which oversees the clinical
practice for the entire UC San Diego Health System). Dr
Sandborn has published more than 569 peer-reviewed arti-
cles including articles in theNew England Journal of Medicine,
Nature, Lancet, Journal of the American Medical Association,
Annals of Internal Medicine, and Gastroenterology. His h-index
is 105. His research interests are clinical trials and clinical
pharmacology related to inﬂammatory bowel disease.Intestinal Disorders
(ID) Section: Kim E.
Barrett, PhD, AGAF
Kim Barrett, a native of the
United Kingdom, obtained her
BSc and PhD degrees from the
Department of Chemistry at Uni-
versity College London. After a
postdoctoral fellowship at the
National Institutes of Health, she
joined the faculty of UC San Diego
School of Medicine in 1985, and
rose to the rank of Professor of Medicine in 1996, and
Distinguished Professor of Medicine in 2015. Her research
interests center on the normal and abnormal biology of the
intestinal epithelium and their relevance to a variety of
digestive diseases including inﬂammatory bowel diseases,
infectious diarrheal diseases, and peptic ulcer disease. She
has received a number of honors for her research,
including the Bowditch and Davenport Lectureships of the
American Physiological Society, the Bayliss-Starling Prize
Lectureship from the Physiological Society of the United
Kingdom and Ireland, and the degree of Doctor of Medical
Science, honoris causa, from Queens University Belfast. She
has been highly active in professional societies and in
scholarly editing, and is a Past President of the American
Physiological Society and the current Editor-in-Chief of The
Journal of Physiology. She has served on numerous com-
mittees for the AGA, including as an elected member of the
AGA Institute Council and a member of the Governing
Board. She is the author or editor of several books and
monographs (including 2 editions of the textbook,
“Gastrointestinal Physiology,” which also has been trans-
lated into Spanish and Portuguese), and more than 200
peer-reviewed journal articles, book chapters, and reviews.
In 2006, she was appointed as Dean of the Graduate Divi-
sion at the University of California San Diego. In this ca-
pacity, she serves as a member of the senior academic
management team and oversees the recruitment, academic
advancement, and climate for more than 5000 masters and
doctoral students.Neurogastroenterology
and Motility (NGM)
Section: Jackie D.
Wood, PhD, AGAF, RFF
Jackie Wood is a professor in the
Department of Physiology and Cell
Biology and in the Department of
Internal Medicine at the Ohio State
University College of Medicine. He
received his doctorate in 1969 from
the Department of Physiology and
Biophysics at the University of Illinois and was appointed as
an Assistant Professor at the University of Kansas School of
Medicine and Medical Center in 1971, and promoted to Pro-
fessor in 1979. He was appointed as Professor and Chairman
in the Department of Physiology of the University of Nevada
School of Medicine from 1979 to 1985, and Professor and
Chairman in the Department of Physiology and Professor of
Internal Medicine in the Ohio State University College of
Medicine in 1985–1997. Dr Wood was inducted as a Fellow
of the AGA in 2006. DrWood’s honors and awards include the
following: NIH Career Development Award; Alexander von
Humboldt Fellowship, Germany; University of Kansas Chan-
cellor’s Award (1975: $1000) for Excellence in Teaching;
Professor-of-the-Year Award, Medical Class of 1983, Univer-
sity of Nevada School of Medicine; The Ohio State University
College of Medicine Excellence in Teaching Award; Honorary
Citizen of the City of Atsugi, Japan; Distinguished Lecturer,
World Congress of Gastroenterology, Sydney, Australia;
Distinguished Faculty Appointment to the World Congress of
Gastroenterology, Los Angeles, CA; and a merit award (2008:
$10,000) for excellence in research and teaching in the Ohio
State University College of Medicine. Dr Wood also is a Hon-
orary Professor of Pharmacology at Weifang Medical Uni-
versity, China.Obesity, Metabolism
and Nutrition (OMN)
Section: Patrick Tso,
PhD
Patrick Tso is a distinguished
career investigator who has men-
tored numerous predoctoral and
postdoctoral trainees, as well as
several clinical fellows, and has
inspired many to go on as suc-
cessful independent researchers.
He is theMary Emery Professor of Pathology at the University
of Cincinnati. Dr Tso’s highly successful career there has
included positions such as the Director of the NIH-funded
Cincinnati Mouse Metabolic Phenotyping Center and Direc-
tor of the Center for Lipid Research for 6 years. He was the
recipient of the Daniel Drake Medal, the highest honor
bestowed to a faculty at the College of Medicine. Dr Tso’s
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secretion of chylomicrons. His seminal work on apolipopro-
tein A-IV deﬁned important roles for this gut protein. He also
has studied the role of gut inﬂammatory factors induced by
lipid absorption that may contribute to insulin resistance and
metabolic syndrome. His most recent work involves deﬁning
the role and mechanisms of the regulation of chylomicron
formation and secretion by apolipoprotein A-V. He has been
funded continuously by the NIH since the early 1980s with
multiple R01 grants, as well as participation in NIH Study
Sections and the National Institute of Diabetes and Digestive
and Kidney Diseases Advisory Council. Dr Tso’s love of
teaching, patience, and infectious enthusiasm over discov-
eries in the laboratory inspired many to pursue a successful
NIH-funded research career with various aspects of gastro-
intestinal physiology. He is a highly successful and productive
basic scientist and he has distinguished himself especially as a
consummate mentor of predoctoral and postdoctoral
trainees, especially young physician scientists, which repre-
sent an “endangered species.”Pancreatic Disorders
(PAN) Section: David C.
Whitcomb, MD, PhD,
AGAF
David Whitcomb is the Giant
Eagle Professor of Cancer Genetics;
Professor of Medicine, Cell Biology
& Physiology and Human Genetics;
and Chief of the Division of
Gastroenterology, Hepatology and
Nutrition at the University ofPittsburgh. Dr Whitcomb has dedicated his career to
helping patients with pancreatic diseases. With more than
2 decades of continuous funding from the NIH, Dr Whit-
comb assembled effective teams of multidisciplinary phy-
sicians and scientists for basic, translational, and clinical
research. He developed paradigm-shifting models
including equation-based models for pancreatic duct ﬂuid
secretion, TIGAR-O, sentinel acute pancreatitis event,
clinical models for personalized medicine, and the Matrix
Academic division. As world leaders in pancreas genetics,
his team discovered PRSS1 in hereditary pancreatitis,
CLD2 in alcoholic pancreatitis, and PALLD in pancreatic
cancer. He founded the North American Pancreatic Study
Group to conduct North American Pancreatic Study, Pan-
creasFest to facilitate multi-institute cooperation, and
Collaborative Alliance for Pancreatic Education and
Research to support your physician scientists.Most current article
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